cardiometabolic health

CKM Syndrome Staging: The First Multi-Society AHA/ACC/ADA/ASN Guideline, June 2026

CKM Syndrome Staging: What the First-Ever AHA/ACC/ADA/ASN Guideline Means for Primary Care

By Dr. Anush S. Pillai, DO, FAAFP | Reviewed by CME Travel Academy Faculty 7 min read  ·  Reviewed August 2026 Accredited CME: ✓ AMA PRA Category 1 Credit™ ✓ AAFP Prescribed ✓ AOA Category 2 ✓ 12 Credits per Conference On June 9, 2026, the American Heart Association, American College of Cardiology, American Diabetes […]

CKM Syndrome Staging: What the First-Ever AHA/ACC/ADA/ASN Guideline Means for Primary Care Read More »

CME Travel Academy clinical update graphic: oral GLP-1 treatment for obesity, orforglipron, SELECT trial, 20% MACE risk reduction, 11.2% weight loss, 12 CME hours

Oral GLP-1 Treatment for Obesity: Orforglipron, the SELECT Trial, and the New 2026 Primary Care Playbook

By Dr. Vimal George, MD | Reviewed by CME Travel Academy Faculty8 min read  ·  Reviewed July 2026 Accredited CME: ✓ AMA PRA Category 1 Credit™ ✓ AAFP Prescribed ✓ AOA Category 2 ✓ 12 Credits per Conference In this article: Obesity Is Now a Cardiovascular Diagnosis Orforglipron Changes the Access Equation Injectable Incretins Still

Oral GLP-1 Treatment for Obesity: Orforglipron, the SELECT Trial, and the New 2026 Primary Care Playbook Read More »

ADA 2026 Guidelines Highlights

What’s New in the ADA 2026 Diabetes Guidelines (compared to 2025)

The American Diabetes Association (ADA) Standards of Care in Diabetes—2026 brings important updates that reflect the latest evidence and real-world clinical experience in diabetes care. These guidelines — published as an annual supplement to Diabetes Care — guide clinicians on diagnosis, management, prevention, and complication care across the lifespan. Join us for an in depth

What’s New in the ADA 2026 Diabetes Guidelines (compared to 2025) Read More »